SCHEMBL15096322

SCHEMBL15096322

Cc1cc(Oc2ccc(C=O)c(C(F)(F)F)c2)ccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
AR P10275 8/20 0.39
MCL1 Q07820 1/20 0.38
CHEK2 O96017 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
RHEB Q15382 1/20 0.36
HTR2A P28223 1/20 0.36
SLC6A4 P31645 1/20 0.36
KCNH2 Q12809 1/20 0.36
KDR P35968 2/20 0.35
BRAF P15056 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ICAM1 P05362 1/20 0.35
SELE P16581 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL883449 0.88 CHEK2 (0.46) ARCHEK2KDRBRAFSCN9A
SCHEMBL15823461 0.82 AR (0.56) ARCHEK2KDM4EHTR2ASLC6A4
SCHEMBL15096320 0.82 TDP1 (0.47) MEN1KMT2AMCL1KDM4EPOLB
SCHEMBL876289 0.81 CHEK2 (0.47) ARCHEK2KDRBRAFSCN9A
SCHEMBL8550194 0.79 AR (0.44) MEN1KMT2AARPOLBSMN1; SMN2
SCHEMBL15096324 0.79 AR (0.59) AR
SCHEMBL364785 0.78 ALDH1A1 (0.55) MEN1KMT2AARCHEK2BRAF
SCHEMBL18957656 0.78 LMNA (0.46) KMT2AARNPC1RAB9ASMN1; SMN2
SCHEMBL6142741 0.78 SCN9A (0.44) KMT2AARPOLBKDRSCN9A
SCHEMBL15096323 0.76 HTR2A (0.45) MEN1KMT2AARMCL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 MEN1 2428/4885KMT2A 4340/4885AR 3517/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 MEN1 2428/4885KMT2A 4340/4885AR 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.